Benefits of Menopause Hormone Therapy

Systemic estrogen, with a progestogen when needed, is the most effective treatment for menopause-related hot flashes and night sweats. Systemic means the hormones reach the bloodstream in amounts that affect the whole body. Tablets, skin patches, gels, and sprays can deliver this treatment.

Useful improvement can include fewer episodes, less intense heat, or fewer nights spent waking and changing clothes. To judge your response, record the pattern that matters to you: episodes during meetings, awakenings overnight, or symptoms that interrupt a usual activity.

The first prescription may need adjustment. Dose, formulation, consistent use, and side effects all influence whether it suits you. Persistent symptoms deserve a review of the treatment and diagnosis, with an earlier appointment if they remain difficult to manage.

Lower estrogen after menopause can affect vaginal tissues. Symptoms can include dryness, irritation, burning, and pain with penetration. Estrogen treatment can improve these symptoms, but the appropriate route depends on whether you also need treatment for hot flashes.

When low-dose vaginal treatment is enough

If vaginal symptoms are the main concern, local estrogen may provide the needed treatment with much lower systemic exposure. Creams, tablets, inserts, and low-dose rings are options. Moisturizers or lubricants can also be used, with the choice guided by symptoms and preference.

Some women need vaginal estrogen alongside systemic HRT because vaginal symptoms remain bothersome. A history of breast cancer requires a specific discussion of nonhormonal care, ongoing cancer treatment, and the uncertainty around recurrence risk. Local therapy should not be selected by applying the systemic risk discussion without considering its much lower exposure.

When night sweats repeatedly wake you, reducing them can make sleep less disrupted. Follow whether awakenings decrease and how you feel during the day. If insomnia continues after hot flashes improve, assess it separately. Cognitive behavioral therapy for insomnia is an established treatment for persistent sleep difficulty.

Mood needs a more specific assessment. NICE advises considering HRT for depressive symptoms that begin around the same time as other menopause symptoms and do not meet criteria for a depression diagnosis. That is a narrower recommendation than prescribing hormones for every episode of low mood or anxiety.

Diagnosed or suspected depression requires appropriate depression care alongside menopause treatment. HRT also is not recommended for dementia prevention. Difficulty concentrating should prompt questions about sleep, mood, other medication, and physical symptoms, with investigation guided by the history.

Systemic hormone therapy prevents bone loss and reduces fracture risk while used. The benefit decreases after treatment stops, so bone health remains relevant when deciding to continue or discontinue HRT.

Bone treatment should reflect your own fracture risk. A previous fragility fracture, established osteoporosis, or another important risk factor may require a bone-health assessment and a plan beyond symptom treatment. Exercise, adequate nutrition, and fall prevention remain part of that plan.

Premature ovarian insufficiency, which occurs before age 40, creates a different treatment context from menopause at the usual age. NICE recommends hormonal replacement, unless contraindicated, until at least the usual age of natural menopause. This addresses the consequences of early hormone loss as well as symptoms.

• Name the symptoms you want to change, with examples of how they affect your day.
• Agree on the appropriate route: systemic treatment, local treatment, or both.
• Review whether you need a progestogen for uterine protection.
• Set a follow-up appointment to assess benefit and any new side effects or bleeding.

HRT should not be prescribed solely for weight loss or prevention of cardiovascular disease or dementia. Its established benefits must be considered alongside breast, uterine, clotting, and other risks. For otherwise healthy symptomatic women younger than 60 or within 10 years of menopause, that balance is generally favorable when there are no contraindications.

An improvement in daily life is worth recording, but the treatment also needs to remain medically suitable. NICE recommends review at three months and then annually, with earlier contact when symptoms fail to improve or adverse effects develop.